Instil Bio, Inc. (TIL) investor relations documents from the company's IR site: 7 press releases. Read in-app with summaries. First-party data.
| Published | Type | Document |
|---|---|---|
| 2026-08-13 | Press release | Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-05-15 | Press release | Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-03-27 | Press release | Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update |
| 2026-01-06 | Press release | Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement |
| 2025-11-13 | Press release | Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
| 2025-09-10 | Press release | Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 |
| 2025-08-13 | Press release | Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
TIL overview · TIL earnings · TIL financials · TIL KPIs · TIL ownership · TIL peers · TIL filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.